Literature DB >> 30820642

Real-world survival data of device-related thrombus following left atrial appendage closure: 4-year experience from a single center.

Yuan Bai1,2, Xin Xue1,3, Erich Duenninger1, Manuela Muenzel1, Lisheng Jiang1,3, Thorsten Keil4, Adam Fazakas1, Jiangtao Yu5,6.   

Abstract

This study aimed to estimate the incidence and risk factors of device-related thrombus (DRT) following percutaneous left atrial appendage closure (LAAC) in real-world practices. Between February 2012 and December 2016, 319 consecutive patients with atrial fibrillation underwent percutaneous LAAC using WATCHMAN, WATCHMAN Flx, Amplatzer cardiac plug, and Amulet devices. All patients underwent transesophageal echocardiography (TEE) at a minimum of three time points; periprocedurally, at 45 days, and at 6 months. Other clinical parameters were also evaluated, and a comparison between patients with DRT and those not suffering from DRT was done. The percutaneous LAAC was successfully performed in 97.8% of the patients. DRT was detected in 14 (4.49%) patients; of the 14 patients, DRT was detected in 3 patients at acute phase, 8 patients at subacute phase, 2 patients at late phase and 1 patient at very late phase. Most of the DRT originated from the central screw of device. In 6 out of 14 patients, DRT was successfully resolved by oral anticoagulation. Higher HAS-BLED score (4.1 ± 1.2 vs. 3.5 ± 1.1, p = 0.042) was more frequent in patients with DRT. Multivariable analysis showed that residual peri-device leak may result in a predisposition to DRT (p = 0.023). The incidence of DRT after percutaneous LAAC was acceptable, as a part of the DRT was resolved with oral anticoagulation. Residual peri-device leak was associated with DRT. Optimal implantation without peri-device gap, individual antithrombotic regimens, and careful monitoring with TEE follow-up could be conducive to the prevention of DRT.

Entities:  

Keywords:  Anticoagulation; Left atrial appendage closure; Percutaneous; Thrombus

Mesh:

Substances:

Year:  2019        PMID: 30820642     DOI: 10.1007/s00380-019-01364-7

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  5 in total

1.  Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure.

Authors:  Roberto Galea; Federico De Marco; Adel Aminian; Nicolas Meneveau; Frederic Anselme; Christoph Gräni; Adrian T Huber; Emmanuel Teiger; Xavier Iriart; Marco Angelillis; Nicolas Brugger; Alessandro Spirito; Noé Corpataux; Anna Franzone; Pascal Vranckx; Urs Fischer; Giovanni Pedrazzini; Francesco Bedogni; Stephan Windecker; Lorenz Räber; Marco Valgimigli
Journal:  J Cardiovasc Transl Res       Date:  2021-04-21       Impact factor: 4.132

2.  Residual flow may increase the risk of adverse events in patients received combined catheter ablation and transcatheter left atrial appendage closure for nonvalvular atrial fibrillation: a meta-analysis.

Authors:  Zhonglin Han; Xiang Wu; Zheng Chen; Wengqing Ji; Xuehua Liu; Yu Liu; Wencheng Di; Xiaohong Li; Hongsong Yu; Xinlin Zhang; Biao Xu; Rong Fang Lan; Wei Xu
Journal:  BMC Cardiovasc Disord       Date:  2019-06-10       Impact factor: 2.298

Review 3.  Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation.

Authors:  Muhammad Ali; Angelos G Rigopoulos; Mammad Mammadov; Abdelrahman Torky; Andrea Auer; Marios Matiakis; Elena Abate; Constantinos Bakogiannis; Stergios Tzikas; Boris Bigalke; Daniel Sedding; Michel Noutsias
Journal:  BMC Cardiovasc Disord       Date:  2020-02-12       Impact factor: 2.298

Review 4.  2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation.

Authors:  He Ben; Ma Changsheng; Wu Shulin
Journal:  Pacing Clin Electrophysiol       Date:  2022-03-18       Impact factor: 1.912

5.  Latest outcomes of transcatheter left atrial appendage closure devices and direct oral anticoagulant therapy in patients with atrial fibrillation over the past 5 years: a systematic review and meta-analysis.

Authors:  Keiichi Takeda; Yusuke Tsuboko; Kiyotaka Iwasaki
Journal:  Cardiovasc Interv Ther       Date:  2022-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.